Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 0.76 |
| ▸ | HRH1 | P35367 | 2/20 | 0.76 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.76 |
| ▸ | DRD2 | P14416 | 5/20 | 0.74 |
| ▸ | DRD4 | P21917 | 5/20 | 0.74 |
| ▸ | DRD3 | P35462 | 3/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.74 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.74 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5606161 | 0.98 | HRH4 (0.97) | HRH4HRH2HRH1HRH3DRD2 | |
| SCHEMBL9221434 | 0.88 | HRH4 (0.78) | HRH4HRH2HRH1HRH3DRD2 | |
| Loxapine SCHEMBL94146 | 0.85 | HRH4 (1.00) | HRH4HRH2HRH1HRH3DRD2 | |
| Loxapine SCHEMBL30324780 | 0.85 | HRH4 (1.00) | HRH4HRH2HRH1HRH3DRD2 | |
| Loxapine SCHEMBL29482385 | 0.85 | HRH4 (1.00) | HRH4HRH2HRH1HRH3DRD2 | |
| Isoloxapine SCHEMBL2738975 | 0.85 | HRH4 (1.00) | HRH4HRH2HRH1HRH3DRD2 | |
| SCHEMBL7412478 | 0.85 | HRH4 (0.74) | HRH4HRH2HRH1HRH3DRD2 | |
| SCHEMBL2615391 | 0.85 | HRH4 (0.74) | HRH4HRH2HRH1HRH3DRD2 | |
| SCHEMBL2615385 | 0.85 | HRH4 (0.74) | HRH4HRH2HRH1HRH3DRD2 | |
| Loxapine SCHEMBL19386241 | 0.85 | HRH4 (1.00) | HRH4HRH2HRH1HRH3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010048264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-1593676-B1 | 8-Chloro-11-(4-(2'-hydroxyethyl)piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine of atypical anti-psychotic activity and having a low affinity for the dopamine D2 receptor | CAMH (CA) | 2009-10-07 | — | — | EP | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090149442-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | KAPUR SHITIJ | 2009-06-11 | — | — | US | disclosed |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | COMBINATORX, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1593676-A1 | 8-Chloro-11-(4-(2'-hydroxyethyl)piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine of atypical anti-psychotic activity and having a low affinity for the dopamine D2 receptor | Neuromolecular, Inc. (CA) | 2005-11-09 | — | — | EP | disclosed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | disclosed |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| US-6890919-B2 | Atypical antipsychotic agents having low affinity for the D2 receptor | KAPUR SHITIJ (CA) | 2005-05-10 | — | — | US | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | HRH4 171/4885HRH2 1025/4885HRH1 558/4885 |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | IL5, TNF, LTC4S | HRH4 159/4885HRH2 205/4885HRH1 276/4885 |
| US-20090149442-A1 | Atypical antipsychotic agents having low affinity for the D2 receptor | DRD2, OPRD1, GRIN2A | HRH4 493/4885HRH2 475/4885HRH1 628/4885 |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | HRH4 4/4885HRH2 7/4885HRH1 13/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | HRH4 675/4885HRH2 814/4885HRH1 1423/4885 |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | IL5, TNF, LTC4S | HRH4 159/4885HRH2 205/4885HRH1 276/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HRH4 354/4885HRH2 583/4885HRH1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.